Drug-Induced Interstitial Lung Disease in Lung Cancer Patients
This review discusses the incidence, risk factors, clinical and radiographic features, and management strategies for D-ILD in the context of current systemic treatments for lung cancer. A practical framework for differential diagnosis is also provided to support clinical decision-making.
Authors
- Valerie Van Ballaer (ORCID: https://orcid.org/0000-0001-6881-7533)
- Gilles Vanhandsaeme
- Gilles Defraene (ORCID: https://orcid.org/0000-0002-3622-4925)
- Maarten Lambrecht (ORCID: https://orcid.org/0000-0002-8746-2691)
- Pierre Van Mol
- Elena Donders
- Els Wauters (ORCID: https://orcid.org/0000-0002-0115-0030)
- Walter De Wever (ORCID: https://orcid.org/0000-0003-2304-2281)
- Karolien Viskens
Institutions
- VIB-KU Leuven Center for Cancer Biology (BE)
- KU Leuven (BE)
Publication Details
- Journal
- Respiration
- Published
- 2025-11-12
- DOI
- https://doi.org/10.1159/000548862
- Primary Topic
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Fonds Wetenschappelijk Onderzoek
- Fondation contre le Cancer